Thrombophilia and its impact on pregnancy Adapted from Pabinger I, Thrombophilia and its impact on pregnancy, Hamostaseologie 2008;28(3):130-4. Published with permission from Schattauer GmbH.

Thrombosis Research

Volumn 123, Issue SUPPL. 3, 2009, Pages

  Pabinger, Ingrid ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Abortion; Fetal loss; Pre eclampsia; Pregnancy; Stillbirth; Thrombophilia

Indexed keywords

ACETYLSALICYLIC ACID; DALTEPARIN; ENOXAPARIN; HEPARIN; PHOSPHOLIPID ANTIBODY;

ABORTION; ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG EFFICACY; ENVIRONMENTAL FACTOR; HUMAN; MONOTHERAPY; PREECLAMPSIA; PREGNANCY; PREGNANCY OUTCOME; PREMATURITY; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; SCREENING; SPONTANEOUS ABORTION; THROMBOEMBOLISM; THROMBOPHILIA; THROMBOSIS PREVENTION;

ABORTION, SPONTANEOUS; ANTICOAGULANTS; FEMALE; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; INFANT, NEWBORN; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY COMPLICATIONS, CARDIOVASCULAR; PREGNANCY COMPLICATIONS, HEMATOLOGIC; PREGNANCY OUTCOME; RISK FACTORS; THROMBOPHILIA; THROMBOSIS; VENOUS THROMBOEMBOLISM;

EID: 59449084799     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2008.08.013     Document Type: Article

References (58)

1. Bick R.L. Recurrent miscarriage syndrome due to blood coagulation protein/platelet defects: prevalence, treatment and outcome results. DRW Metroplex Recurrent Miscarriage Syndrome Cooperative Group. Clin Appl Thromb Hemost 6 (2000) 115-125
2. Clark P., Brennand J., Conkie J.A., McCall F., Greer I.A., and Walker I.D. Activated protein C sensitivity, protein C, protein S and coagulation in normal pregnancy. Thromb Haemost 79 (1998) 1166-1170
3. Stirling Y., Woolf L., North W.R., Seghatchian M.J., and Meade T.W. Haemostasis in normal pregnancy. Thromb Haemost 52 (1984) 176-182
4. Comp P.C., Thurnau G.R., Welsh J., and Esmon C.T. Functional and immunologic protein S levels are decreased during pregnancy. Blood 68 (1986) 881-885
5. Bonnar J., McNicol G.P., and Douglas A.S. Fibrinolytic enzyme system and pregnancy. Br Med J 3 (1969) 387-389
6. Beller F.K., and Ebert C. The coagulation and fibrinolytic enzyme system in pregnancy and in the puerperium. Eur J Obstet Gynecol Reprod Biol 13 (1982) 177-197
7. Sondheimer S. Abortion. Encycl Reprod 1 (1999) 1-6
8. Preston F.E., Rosendaal F.R., Walker I.D., et al. Increased fetal loss in women with heritable thrombophilia. Lancet 348 (1996) 913-916
9. Rai R., Regan L., Hadley E., Dave M., and Cohen H. Secondtrimester pregnancy loss is associated with activated C resistance. Br J Haematol 92 (1996) 489-490
10. Sanson B.J., Friederich P.W., Simioni P., et al. The risk of abortion and stillbirth in antithrombin-, protein C-, and protein S-deficient women. Thromb Haemost 75 (1996) 387-388
11. Kupferminc M.J., Eldor A., Steinman N., et al. Increased frequency of genetic thrombophilia in women with complications of pregnancy. N Engl J Med 340 (1999) 9-13
12. Gris J.C., Ripart-Neveu S., Maugard C., et al. Respective evaluation of the prevalence of haemostasis abnormalities in unexplained primary early recurrent miscarriages. The Nimes Obstetricians and Haematologists (NOHA) Study. Thromb Haemost 77 (1997) 1096-1103
13. Grandone E., Margaglione M., Colaizzo D., et al. Factor V Leiden is associated with repeated and recurrent unexplained fetal losses. Thromb Haemost 77 (1997) 822-824
14. Martinelli I., Taioli E., Cetin I., et al. Mutations in coagulation factors in women with unexplained late fetal loss. N Engl J Med 343 (2000) 1015-1018
15. Younis J.S., Brenner B., Ohel G., Tal J., Lanir N., and Ben-Ami M. Activated protein C resistance and factor V Leiden mutation can be associated with first-as well as second-trimester recurrent pregnancy loss. Am J Reprod Immunol 43 (2000) 31-35
16. Pihusch R., Buchholz T., Lohse P., et al. Thrombophilic gene mutations and recurrent spontaneous abortion: prothrombin mutation increases the risk in the first trimester. Am J Reprod Immunol 46 (2001) 124-131
17. Alonso A., Soto I., Urgelles M.F., Corte J.R., Rodriguez M.J., and Pinto C.R. Acquired and inherited thrombophilia in women with unexplained fetal losses. Am J Obstet Gynecol 187 (2002) 1337-1342
18. Rasmussen A., and Ravn P. High frequency of congenital thrombophilia in women with pathological pregnancies?. Acta Obstet Gynecol Scand 83 (2004) 808-817
19. Gris J.C., Quere I., Sanmarco M., et al. Antiphospholipid and antiprotein syndromes in non-thrombotic, non-autoimmune women with unexplained recurrent primary early foetal loss. The Nimes Obstetricians and Haematologists Study NOHA. Thromb Haemost 84 (2000) 228-236
20. Rai R., Shlebak A., Cohen H., et al. Factor V Leiden and acquired activated protein C resistance among 1000 women with recurrent miscarriage. Hum Reprod 16 (2001) 961-965
21. Carp H., Salomon O., Seidman D., Dardik R., Rosenberg N., and Inbal A. Prevalence of genetic markers for thrombophilia in recurrent pregnancy loss. Hum Reprod 17 (2002) 1633-1637
22. Dudding T.E., and Attia J. The association between adverse pregnancy outcomes and maternal factor V Leiden genotype: a meta-analysis. Thromb Haemost 91 (2004) 700-711
23. Kovalevsky G., Gracia C.R., Berlin J.A., Sammel M.D., and Barnhart K.T. Evaluation of the association between hereditary thrombophilias and recurrent pregnancy loss: a meta-analysis. Arch Intern Med 164 (2004) 558-563
24. Rey E., Kahn S.R., David M., and Shrier I. Thrombophilic disorders and fetal loss: a meta-analysis. Lancet 361 (2003) 901-908
25. Hashimoto K., Shizusawa Y., Shimoya K., et al. The factor V Leiden mutation in Japanese couples with recurrent spontaneous abortion. Hum Reprod 14 (1999) 1872-1874
26. Robertson L., Wu O., Langhorne P., Twaddle S., Clark P., Lowe G.D., et al., The Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) Study. Thrombophilia in pregnancy: a systematic review. Br J Haematol 132 2 (2006 Jan) 171-196
27. Lindqvist P.G., Svensson P.J., Marsaal K., Grennert L., Luterkort M., and Dahlback B. Activated protein C resistance (FV:Q506) and pregnancy. Thromb Haemost 81 (1999) 532-537
28. Murphy R.P., Donoghue C., Nallen R.J., et al. Prospective evaluation of the risk conferred by factor V Leiden and thermolabile methylenetetrahydrofolate reductase polymorphisms in pregnancy. Arterioscler Thromb Vasc Biol 20 (2000) 266-270
29. Carp H., Dolitzky M., and Inbal A. Thromboprophylaxis improves the live birth rate in women with consecutive recurrent miscarriages and hereditary thrombophilia. J Thromb Haemost 1 (2003) 433-438
30. Kupferminc M.J., Fait G., Many A., et al. Low-molecular-weight heparin for the prevention of obstetric complications in women with thrombophilias. Hypertens Pregnancy 20 (2001) 35-44
31. Sanson B.J., Lensing A.W., Prins M.H., et al. Safety of low-molecular-weight heparin in pregnancy: a systematic review. Thromb Haemost 81 (1999) 668-672
32. Tzafettas J., Mamopoulos A., Anapliotis A., et al. Thromboprophylaxis throughout pregnancy in women with previous history of recurrent miscarriages of unknown aetiology. Clin Exp Obstet Gynecol 29 (2002) 267-270
33. Gris J.C., Mercier E., Quere I., et al. Low-molecular-weight heparin versus low-dose aspirin in women with one fetal loss and a constitutional thrombophilic disorder. Blood 103 (2004) 3695-3699
34. Saftlas A.F., Olson D.R., Franks A.L., Atrash H.K., and Pokras R. Epidemiology of preeclampsia and eclampsia in the United States, 1979 1986. Am J Obstet Gynecol 163 (1990) 460-465
35. Brenner B., Lanir N., and Thaler I. HELLP syndrome associated with factor V R506Q mutation. Br J Haematol 92 (1996) 999-1001
36. Dizon-Townson D.S., Nelson L.M., Easton K., and Ward K. The factor V Leiden mutation may predispose women to severe preeclampsia. Am J Obstet Gynecol 175 (1996) 902-905
37. van Pampus M.G., Dekker G.A., Wolf H., et al. High prevalence of hemostatic abnormalities in women with a history of severe preeclampsia. Am J Obstet Gynecol 180 (1999) 1146-1150
38. Kosmas I.P., Tatsioni A., and Ioannidis J.P. Association of Leiden mutation in factor V gene with hypertension in pregnancy and pre-eclampsia: a meta-analysis. J Hypertens 21 (2003) 1221-1228
39. Kosmas I.P., Tatsioni A., and Ioannidis J.P. Association of C677T polymorphism in the methylenetetrahydrofolate reductase gene with hypertension in pregnancy and pre-eclampsia: a meta-analysis. J Hypertens 22 (2004) 1655-1662
40. Morrison E.R., Miedzybrodzka Z.H., Campbell D.M., et al. Prothrombotic genotypes are not associated with pre-eclampsia and gestational hypertension: results from a large population-based study and systematic review. Thromb Haemost 87 (2002) 779-785
41. Caritis S., Sibai B., Hauth J., et al. Low-dose aspirin to prevent preeclampsia in women at high risk. National Institute of Child Health and Human Development Network of Maternal Fetal Medicine Units. N Engl J Med 338 (1998) 701-705
42. Pabinger I., Grafenhofer H., Kyrle P.A., et al. Temporary increase in the risk for recurrence during pregnancy in women with a history of venous thromboembolism. Blood 100 (2002) 1060-1062
43. Conard J., Horellou M.H., Van Dreden P., Lecompte T., and Samama M. Thrombosis and pregnancy in congenital deficiencies in AT III, protein C or protein S: study of 78 women. Thromb Haemost 63 (1990) 319-320
44. Pabinger I., and Schneider B. Thrombotic risk in hereditary antithrombin III, protein C, or protein S deficiency. A cooperative, retrospective study. Gesellschaft f̈ur Thrombose-und Ḧamostaseforschung (GTH) Study Group on Natural Inhibitors. Arterioscler Thromb Vasc Biol 16 (1996) 742-748
45. Tengborn L., Bergqvist D., Matzsch T., Bergqvist A., and Hedner U. Recurrent thromboembolism in pregnancy and puerperium. Is there a need for thromboprophylaxis?. Am J Obstet Gynecol 160 (1989) 90-94
46. Pabinger I., Nemes L., Rintelen C., et al. Pregnancy-associated risk for venous thromboembolism and pregnancy outcome in women homozygous for factor V Leiden. Hematol J 1 (2000) 37-41
47. Brill-Edwards P., Ginsberg J.S., Gent M., et al. Safety of withholding heparin in pregnant women with a history of venous thromboembolism. Recurrence of Clot in This Pregnancy Study Group. N Engl J Med 343 (2000) 1439-1444
48. Pabinger I., Grafenhofer H., Kaider A., et al. Risk of pregnancy-associated recurrent venous thromboembolism in women with a history of venous thrombosis. J Thromb Haemost 3 (2005) 949-954
49. Triplett D.A. Antiphospholipid antibodies and recurrent pregnancy loss. Am J Reprod Immunol 20 2 (1989 Jun) 52-67
50. Meinardi J.R., Middeldorp S., de Kam P.J., et al. Increased risk for fetal loss in carriers of the factor V Leiden mutation. Ann Intern Med 130 (1999) 736-739
51. Tormene D., Simioni P., Prandoni P., et al. The risk of fetal loss in family members of probands with factor V Leiden mutation. Thromb Haemost 82 (1999) 1237-1239
52. Pabinger I., Grafenhofer H., Kaider A., et al. Preeclampsia and fetal loss in women with a history of venous thromboembolism. Arterioscler Thromb Vasc Biol 21 (2001) 874-879
53. Vossen C.Y., Preston F.E., Conard J., et al. Hereditary thrombophilia and fetal loss: a prospective follow-up study. J Thromb Haemost 2 (2004) 592-596
54. Rai R., Cohen H., Dave M., and Regan L. Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies). Br Med J 314 (1997) 253-257
55. Kutteh W.H. Antiphospholipid antibody-associated recurrent pregnancy loss: treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone. Am J Obstet Gynecol 174 (1996) 1584-1589
56. Farquharson R.G., Quenby S., and Greaves M. Antiphospholipid syndrome in pregnancy: a randomized, controlled trial of treatment. Obstet Gynecol 100 (2002) 408-413
57. Bauersachs R.M., Dudenhausen J., Faridi A., Fischer T., Fung S., Geisen U., et al., EThIG Investigators. Risk stratification and heparin prophylaxis to prevent venous thromboembolism in pregnant women. Thromb Haemost 98 6 (2007 Dec) 1237-1245
58. Greer I.A., and Nelson-Piercy C. Low-molecular-weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: a systematic review of safety and efficacy. Blood 106 2 (2005 Jul 15) 401-407